This study interviews healthcare providers (HCPs) about their real-world treatment decisions for patients on GLP-1 agonist treatment. It collects patient background and prescribing rationale to understand the clinical drivers, barriers, and practice patterns for their use.
Nearly half of HCPs reported weight loss as a top treatment decision driver, with weight loss positioned as equally or more important than A1C reduction in several treatment selections for T2D patients.
One-fifth of HCPs cite cardiovascular risk reduction as a top driver for GLP-1 selection, with Ozempic consistently chosen over Mounjaro for patients with heart disease due to established CV benefit profile and concerns about Mounjaro's lack of cardiovascular data.
15% of HCPs abandon clinically preferred treatments due to insurance barriers, with 70% citing affordable pricing as the top needed improvement, followed by patient samples (35%) and better insurance coverage (30%).
Our Patient Scribe AI, part of the Sagan suite, transforms patient chart audits. It allows HCPs to dictate patient information by voice, enabling the fast and scalable collection of rich, qualitative data from real-world cases.
LEARN MORE
Voice-first approach captures the nuances of treatment decisions while reducing user fatigue, enabling HCPs to provide quality insights naturally.
High insight density reports curated specifically for brand teams, leveraging conversations that are natural to humans.
Understand the "whys behind the what" to take actions with a nuanced view providing deeper insights through natural conversations.
In several instances, weight loss is positioned as equally or more important than A1C reduction in treatment selection. Almost half of HCPs reported weight loss as a top treatment decision driver.
1/5th of HCPs reported cardiovascular risk reduction as a top driver when choosing between GLP-1 therapies, especially when patients have comorbidities. Ozempic is often chosen over Mounjaro for patients with heart disease due to its established CV benefit profile. 4 HCPs out of 53 reported ruling out Mounjaro due to a lack of CV benefits.
While clinical benefits remain the primary consideration, insurance coverage often determines the final prescribing decision when preferred GLP-1 medications aren’t covered. Physicians frequently consider GLP-1 agonist treatment options but default to those with better coverage or faster approval processes. Patients are sometimes switched due to lack of formulary inclusion. Notably, 13% of HCPs reported abandoning a treatment they initially favored due to cost or insurance barriers.
Providers emphasized that high medication costs and copays are major barriers for patients. They want pharmaceutical companies to reduce prices, offer better savings cards, coupons, and incentive programs to help patients afford GLP-1 drugs for weight loss or GLP-1 for type 2 diabetes.
HCPs want pharmaceutical companies to provide more free samples to initiate therapy easily and support patients during dose titration. Clinical reprint materials and clear titration guidelines are requested.
Issues with monthly prior authorization requirements, unclear insurance coverage, and formulary status limitations. They want better collaboration with payers to improve coverage and reduce administrative hurdles.
ZoomRx offers a wide range of AI-driven MR tools to empower your team to push beyond boundaries.
LEARN MORE